Trastuzumab and lapatinib are anti HER-2 targeted therapies and may work for prevention of HER2+ breast carcinomas; bicalutamide and enzalutamide are AR antagonists that may impact the disease course of AR+ TNBCs [138]. This evidence concerns the gene AR and breast carcinoma.